These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 28940301)

  • 1. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
    Chaoul A; Milbury K; Spelman A; Basen-Engquist K; Hall MH; Wei Q; Shih YT; Arun B; Valero V; Perkins GH; Babiera GV; Wangyal T; Engle R; Harrison CA; Li Y; Cohen L
    Cancer; 2018 Jan; 124(1):36-45. PubMed ID: 28940301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep moderates the effects of Tibetan yoga for women with breast cancer undergoing chemotherapy.
    Sinclair KL; Kiser E; Ratcliff CG; Chaoul A; Hall MH; Rinpoche TW; Cohen L
    Support Care Cancer; 2022 May; 30(5):4477-4484. PubMed ID: 35107599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
    Liu L; Rissling M; Natarajan L; Fiorentino L; Mills PJ; Dimsdale JE; Sadler GR; Parker BA; Ancoli-Israel S
    Sleep; 2012 Feb; 35(2):237-45. PubMed ID: 22294814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
    Mortimer JE; Waliany S; Dieli-Conwright CM; Patel SK; Hurria A; Chao J; Tiep B; Behrendt CE
    Cancer; 2017 May; 123(10):1810-1816. PubMed ID: 28061004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer.
    Wielgus KK; Berger AM; Hertzog M
    Oncol Nurs Forum; 2009 Jan; 36(1):38-48. PubMed ID: 19136337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series.
    Galantino ML; Greene L; Daniels L; Dooley B; Muscatello L; O'Donnell L
    Explore (NY); 2012; 8(2):127-35. PubMed ID: 22385567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer.
    Yates P; Aranda S; Hargraves M; Mirolo B; Clavarino A; McLachlan S; Skerman H
    J Clin Oncol; 2005 Sep; 23(25):6027-36. PubMed ID: 16135471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue.
    Berger AM; Kuhn BR; Farr LA; Von Essen SG; Chamberlain J; Lynch JC; Agrawal S
    J Clin Oncol; 2009 Dec; 27(35):6033-40. PubMed ID: 19884558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy.
    Liu L; Fiorentino L; Natarajan L; Parker BA; Mills PJ; Sadler GR; Dimsdale JE; Rissling M; He F; Ancoli-Israel S
    Psychooncology; 2009 Feb; 18(2):187-94. PubMed ID: 18677716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
    Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
    Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
    Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.